{
  "guideline": {
    "id": "PA166182737",
    "name": "Annotation of FDA Label for lidocaine and tetracaine and G6PD",
    "objCls": "Label Annotation",
    "source": "FDA",
    "version": 10,
    "url": "https://www.pharmgkb.org/labelAnnotation/PA166182737",
    "relatedChemicals": [
      {
        "id": "PA166182735",
        "name": "lidocaine and tetracaine",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA28469",
        "name": "glucose-6-phosphate dehydrogenase",
        "symbol": "G6PD"
      }
    ],
    "recommendation": false
  },
  "recommendations": [
    {
      "id": "PA166312426",
      "name": "Recommendation Annotation PA166312426",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166182735",
          "name": "lidocaine and tetracaine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216725,
        "html": "<p>&quot;Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, ... are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "G6PD": "Deficient"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166312399",
      "name": "Recommendation Annotation PA166312399",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166182735",
          "name": "lidocaine and tetracaine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452216679,
        "html": "<p>&quot;Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, ... are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "G6PD": "Deficient with CNSHA"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    },
    {
      "id": "PA166315122",
      "name": "Recommendation Annotation PA166315122",
      "population": null,
      "classification": null,
      "relatedChemicals": [
        {
          "id": "PA166182735",
          "name": "lidocaine and tetracaine",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452245661,
        "html": "<p>&quot;Although all patients are at risk for methemoglobinemia, patients with glucose-6-phosphate dehydrogenase deficiency, ... are more susceptible to developing clinical manifestations of the condition. If local anesthetics must be used in these patients, close monitoring for symptoms and signs of methemoglobinemia is recommended.&quot; See label for more information.</p>\n"
      },
      "implications": [],
      "lookupKey": {
        "G6PD": "Variable"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": true
    }
  ],
  "citations": [
    {
      "pmid": null,
      "title": "Drugs@FDA: Drug Product Synera (lidocaine and tetracaine), NDA021623, Galen US Incorporated",
      "authors": [],
      "journal": null,
      "year": -1,
      "_sameAs": "https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=021623"
    }
  ],
  "version": "2024-03-08-14-34"
}